It is with great pleasure that CorFlow announces the arrival of Mr. Timothy Snyder as Chief Financial Officer (CFO). Tim joined the company in December 2018 and brings with him 30 years of experience as a finance professional. He started his career with the “Big Four” accounting firm of Deloitte in Columbus, Ohio (USA). After nine years as a practicing CPA, he went on to serve as Finance Director and CFO for a number of international companies in both the United States and in Europe. Before joining CorFlow, Tim served as the CFO of a Swiss stock-listed contract research organisation (CRO) which served pharmaceutical and biotech companies around the globe. Tim has significant experience in the design and implementation of financial systems including accounting, reporting, budgeting and cash management. He also brings a strong knowledge of corporate governance and general business administration which will help CorFlow through its next stages of growth.
Jon H. Hoem, CorFlow’s CEO and Co-Founder, said: “CorFlow’s business activities have grown to the point where we require a full-time financial executive, and Tim is the ideal fit for us. He has a wide range of experience and has a strong track record of building a financial organisation, with related control systems, from the ground up. Tim will also assist me with broader organisational matters and will be critical to our next rounds of financing planned for the coming years.”
Tim commented on joining the CorFlow team: “After getting to know Jon and the team in recent months, I couldn’t be more excited to build on what they have already achieved and help guide the company through its next phases of growth and success.”
Mrs. Blathnaid Feldman, VP of Regulatory Affairs and Quality Assurance (RAQA), has decided to leave the company to pursue other career objectives. As an interim solution, Mrs. Esther Gerteis, CorFlow’s VP of Clinical, will take over Blathnaid’s responsibilities until a replacement is found. The company has initiated a search for a permanent replacement for the VP RAQA – see the full job description here.
Jon commented on Blathnaid’s decision: "I thank Blathnaid for her important contributions to the CorFlow vision and wish her continued success in her future career."
CorFlow Therapeutics (www.corflow-therapeutics.ch) is incorporated in Baar, Switzerland, and is developing proprietary technologies to measure the coronary microvascular status and provide therapy to the compromised coronary microcirculation at the same time in the catheter laboratory. Microvascular obstruction (MVO) after an acute heart attack is documented to be an independent marker leading to costly complications such as heart failure. The CorFlow technologies will enable interventional cardiologists to treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complication rates in these patients.
Caution: The CorFlow Controlled Flow Infusion (CoFI(TM)) technology is in the early phases of development. It will not be available in Europe, the US or Japan for clinical trials until further notice and is NOT available for sale. This news release contains certain “forward-looking” statements under the Private Securities Litigation Reform Act of 1995. These “forward-looking” statements, which may include, but are not limited to, statements concerning the projections, financial condition, results of operations and businesses of CorFlow are based on management’s current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements. Factors that could cause or contribute to such differences may include, but are not limited to, risks relating to the protection of intellectual property, changes to governmental regulation of medical devices, European or US Food and Drug Administration (FDA) approvals of new products, the impact of competitive products, changes to the competitive environment, the acceptance of new products in the market, conditions of the interventional cardiology industry and the economy and other factors.
Copyright © 2016 – 2018 CorFlow Therapeutics AG. All rights reserved.
CorFlow Therapeutics AG
Neuhofstrasse 5A
CH6340 Baar
Telefon: +41 (79) 6062-902
http://corflow-therapeutics.ch
CEO & Co-Founder
Telefon: +41 (41) 5445556
E-Mail: jhoem@corflow-therapeutics.ch